ConjuPepDB: a Database of Peptide-drug Conjugates

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2020 Oct 30

PMID 33125057

Citations 13

Authors

Balazs Balogh

Marton Ivanczi

Bilal Nizami

Tamas Beke-Somfai

Istvan M Mandity

Affiliations

Soon will be listed here.

Abstract

Peptide-drug conjugates are organic molecules composed of (i) a small drug molecule, (ii) a peptide and (iii) a linker. The drug molecule is mandatory for the biological action, however, its efficacy can be enhanced by targeted delivery, which often also reduces unwanted side effects. For site-specificity the peptide part is mainly responsible. The linker attaches chemically the drug to the peptide, but it could also be biodegradable which ensures controlled liberation of the small drug. Despite the importance of the field, there is no public comprehensive database on these species. Herein we describe ConjuPepBD, a freely available, fully annotated and manually curated database of peptide drug conjugates. ConjuPepDB contains basic information about the entries, e.g. CAS number. Furthermore, it also implies their biomedical application and the type of chemical conjugation employed. It covers more than 1600 conjugates from ∼230 publications. The web-interface is user-friendly, intuitive, and useable on several devices, e.g. phones, tablets, PCs. The webpage allows the user to search for content using numerous criteria, chemical structure and a help page is also provided. Besides giving quick insight for newcomers, ConjuPepDB is hoped to be also helpful for researchers from various related fields. The database is accessible at: https://conjupepdb.ttk.hu/.

Citing Articles

Advancements in mitochondrial-targeted nanotherapeutics: overcoming biological obstacles and optimizing drug delivery.

Li Y, Li X, Wei L, Ye J Front Immunol. 2024; 15:1451989.

PMID: 39483479 PMC: 11524880. DOI: 10.3389/fimmu.2024.1451989.

Neural Influences on Tumor Progression Within the Central Nervous System.

Lv W, Wang Y CNS Neurosci Ther. 2024; 30(10):e70097.

PMID: 39469896 PMC: 11519750. DOI: 10.1111/cns.70097.

Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989.

Al Musaimi O Cancers (Basel). 2024; 16(5).

PMID: 38473389 PMC: 11326481. DOI: 10.3390/cancers16051032.

Molecular Dynamics Simulations of Drug-Conjugated Cell-Penetrating Peptides.

Ivanczi M, Balogh B, Kis L, Mandity I Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765059 PMC: 10535489. DOI: 10.3390/ph16091251.

Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress.

Sun Z, Huang J, Fishelson Z, Wang C, Zhang S Biomedicines. 2023; 11(7).

PMID: 37509610 PMC: 10377493. DOI: 10.3390/biomedicines11071971.

References

Cheng H, Zhu J, Xu X, Qiu W, Lei Q, Han K . Activable Cell-Penetrating Peptide Conjugated Prodrug for Tumor Targeted Drug Delivery. ACS Appl Mater Interfaces. 2015; 7(29):16061-9. DOI: 10.1021/acsami.5b04517. View

Vrettos E, Mezo G, Tzakos A . On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein J Org Chem. 2018; 14:930-954. PMC: 5942387. DOI: 10.3762/bjoc.14.80. View

Horvati K, Bacsa B, Szabo N, Fodor K, Balka G, Rusvai M . Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Tuberculosis (Edinb). 2015; 95 Suppl 1:S207-11. DOI: 10.1016/j.tube.2015.02.026. View

Langer C, OByrne K, Socinski M, Mikhailov S, Lesniewski-Kmak K, Smakal M . Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3(6):623-30. DOI: 10.1097/JTO.0b013e3181753b4b. View

Parvatkar P, Kato N, Uesugi M, Sato S, Ohkanda J . Intracellular Generation of a Diterpene-Peptide Conjugate that Inhibits 14-3-3-Mediated Interactions. J Am Chem Soc. 2015; 137(50):15624-7. DOI: 10.1021/jacs.5b09817. View

Zhang P, Cheetham A, Lock L, Cui H . Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug Chem. 2013; 24(4):604-13. PMC: 3651882. DOI: 10.1021/bc300585h. View

van der Heden van Noort G, van der Horst M, Overkleeft H, van der Marel G, Filippov D . Synthesis of mono-ADP-ribosylated oligopeptides using ribosylated amino acid building blocks. J Am Chem Soc. 2010; 132(14):5236-40. DOI: 10.1021/ja910940q. View

Goswami D, Aguilar Vitorino H, Machini M, Esposito B . Self-assembled penetratin-deferasirox micelles as potential carriers for hydrophobic drug delivery. Biopolymers. 2015; 104(6):712-9. DOI: 10.1002/bip.22672. View

Borodkin V, Schimpl M, Gundogdu M, Rafie K, Dorfmueller H, Robinson D . Bisubstrate UDP-peptide conjugates as human O-GlcNAc transferase inhibitors. Biochem J. 2013; 457(3):497-502. PMC: 3927924. DOI: 10.1042/BJ20131272. View

10.

Perez B, Teixeira C, Figueiras M, Gut J, Rosenthal P, Gomes J . Novel cinnamic acid/4-aminoquinoline conjugates bearing non-proteinogenic amino acids: towards the development of potential dual action antimalarials. Eur J Med Chem. 2012; 54:887-99. DOI: 10.1016/j.ejmech.2012.05.022. View

11.

Tang Q, Cao B, Wu H, Cheng G . Cholesterol-peptide hybrids to form liposome-like vesicles for gene delivery. PLoS One. 2013; 8(1):e54460. PMC: 3559823. DOI: 10.1371/journal.pone.0054460. View

12.

Legigan T, Clarhaut J, Tranoy-Opalinski I, Monvoisin A, Renoux B, Thomas M . The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy. Angew Chem Int Ed Engl. 2012; 51(46):11606-10. DOI: 10.1002/anie.201204935. View

13.

Lee S, Kang S, Ryu J, Na J, Lee D, Han S . Tumor-homing glycol chitosan-based optical/PET dual imaging nanoprobe for cancer diagnosis. Bioconjug Chem. 2014; 25(3):601-10. DOI: 10.1021/bc500020g. View

14.

Szabo I, Bosze S, Orban E, Sipos E, Halmos G, Kovacs M . Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting. J Pept Sci. 2015; 21(5):426-35. DOI: 10.1002/psc.2775. View

15.

Bera S, Zhanel G, Schweizer F . Evaluation of amphiphilic aminoglycoside-peptide triazole conjugates as antibacterial agents. Bioorg Med Chem Lett. 2010; 20(10):3031-5. DOI: 10.1016/j.bmcl.2010.03.116. View

16.

Nitsche C, Schreier V, Behnam M, Kumar A, Bartenschlager R, Klein C . Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture. J Med Chem. 2013; 56(21):8389-403. DOI: 10.1021/jm400828u. View

17.

Agrawal P, Bhalla S, Usmani S, Singh S, Chaudhary K, Raghava G . CPPsite 2.0: a repository of experimentally validated cell-penetrating peptides. Nucleic Acids Res. 2015; 44(D1):D1098-103. PMC: 4702894. DOI: 10.1093/nar/gkv1266. View

18.

Wang Y, Cheetham A, Angacian G, Su H, Xie L, Cui H . Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Adv Drug Deliv Rev. 2016; 110-111:112-126. PMC: 5199637. DOI: 10.1016/j.addr.2016.06.015. View

19.

Engel J, Tinneberg H, Rick F, Berkes E, Schally A . Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer. Curr Drug Targets. 2016; 17(5):488-94. DOI: 10.2174/138945011705160303154717. View

20.

Bera S, Zhanel G, Schweizer F . Synthesis and antibacterial activity of amphiphilic lysine-ligated neomycin B conjugates. Carbohydr Res. 2011; 346(5):560-8. DOI: 10.1016/j.carres.2011.01.015. View